Newron Pharmaceuticals SpA has reported what it claims are “exceptional” results in the 12-month analysis of a phase II open-label trial of evenamide in treatment-resistant schizophrenia. The glutamate modulator produced benefits “of a kind that have never been reported before,” the company said.